Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2246-2253

  Wolff, R A ^a   Evans, D B ^a   Gravel, D M ^a   Lenzi, R ^a   Pisters, P W T ^a   Lee, J E ^a   Janjan, N A ^a   Charnsangavej, C ^a   Abbruzzese, J L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; RADIOSENSITIZING AGENT;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEHYDRATION; DOSE RESPONSE; DRUG POTENCY; DRUG TOLERABILITY; FATIGUE; FEMALE; HOSPITALIZATION; HUMAN; MALE; NAUSEA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION BEAM; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANOREXIA; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 0034880820     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cancer statistics, 1997
2. Survival in 1001 patients with carcinoma of the pancreas
3. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 Patients
4. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy
5. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas
6. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group
7. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
8. Current status of chemotherapy for advanced pancreatic and gastric cancer
9. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A Phase I Eastern Cooperative Oncology Group Trial
10. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma
11. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
12. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
13. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine
14. Phase I trial of radiation concurrent with low-dose gemcitabine for head and neck cancer: High mucosal and pharyngeal toxicity
15. A Phase II study combining gemcitabine with radiotherapy in stage III NSCLC
16. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas
17. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma
18. Gemcitabine-mediated radiosensitization
19. Enhancement of tumor radioresponse in vivo by gemcitabine
20. Preoperative chemoradiation for adenocarcinoma of the pancreas: Excessive toxicity of prophylactic hepatic irradiation
21. Chemoradiotherapy: Radiosensitizing nucleoside analogues
22. Maximizing therapeutic gain with gemcitabine and fractionated radiation
23. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine
24. Preoperative gemcitabine and radiation for resectable adenocarcinoma of the pancreas-preliminary report of a Phase II multi-institution trial
25. A Phase I study of gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer
26. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer